|
|
 | | | |
- close
- close
- close
- close
| |||||||||
This excerpt taken from the ELN 6-K filed Aug 28, 2009. Total
Revenue
Total revenue for the first half of 2009 increased 9% to
$384.6 million from $352.1 million in the same period
of 2008. Total revenue from our Biopharmaceuticals business
increased by 15%, while total revenue from our EDT business
decreased slightly. Total revenue is analysed further between
revenue from the Biopharmaceuticals and EDT business units.
Table of Contents
This excerpt taken from the ELN 6-K filed Mar 30, 2009. Total
Revenue
Refer to page 66 for discussion on revenue from our
Biopharmaceuticals business.
This excerpt taken from the ELN 20-F filed Feb 26, 2009. Total
Revenue
Refer to page 46 for additional discussion on revenue from
our Biopharmaceuticals business.
This excerpt taken from the ELN 6-K filed Mar 31, 2008. Total
Revenue
For analysis of our product revenue and contract revenue by
segment, refer to pages 39 to 41 of the “Financial
Review.”
This excerpt taken from the ELN 20-F filed Feb 28, 2008. Total
Revenue
Total revenue for EDT was $295.5 million in 2007,
$282.1 million in 2006 and $258.6 million in 2005, and
is analyzed below between product revenue and contract revenue.
Table of Contents
EDT product revenue is comprised of manufacturing revenue and
royalties of $269.5 million (2006: $232.4 million;
2005: $204.5 million) and amortized revenue related to
Adalat/Avinza of $4.5 million (2006: $30.7 million;
2005: $34.0 million). Refer to page 42 for additional
discussion on EDT product revenue.
EDT contract revenue, which consists of research revenue and
milestones from R&D activities performed on behalf of third
parties, totaled $21.5 million in 2007, $19.0 million
in 2006 and $20.1 million in 2005. The fluctuations between
years were primarily due to the timing of milestone receipts.
| EXCERPTS ON THIS PAGE:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| |||||||
